News >

Researchers Reveal New Subtype of Cervical Cancer

Allie Strickler @Alliejayes
Published: Monday, Jan 23, 2017

Carolyn E. Banister, MD

Carolyn E. Banister, MD

A new subtype of cervical cancer has been discovered, according to the results of a study published in Oncotarget.

Like most cervical cancers, this novel subtype is also triggered by HPV, but the virus does not direct the growth of the cancer. Thus, therapies used to target these tumors’ distinct genomic pathways may improve outcomes for patients over standard treatment.

An analysis of data from 255 cervical cancer samples in The Cancer Genome Atlas (TCGA) showed that 2 HPV oncogenes that are thought to be integral to cervical cancer growth were expressed at either high levels (HPV-active disease) or low levels (HPV-inactive disease).

"Physicians managing cervical cancer patients should test for HPV oncogene expression in these tumors and consider personalized treatment depending on HPV activity," lead study author Carolyn E. Banister, MD, assistant professor, College of Pharmacy, University of South Carolina, said in a press release.

In an interview with OncLive, Banister highlighted the major findings of her study and the significant therapeutic implications that will follow. She also sheds light on some of the other remaining challenges in the treatment of cervical cancer.

OncLive: Please provide some background for studying this new subtype of cervical cancer.

Banister: It is commonly known that all cervical cancers contain HPV DNA, and we thought they were all the same. But we looked into the TCGA database and discovered that there is a subset of cervical cancers that, although they contain HPV DNA in their genomes, they don’t express the HPV oncogene, and we found that this has therapeutic implications.

How was your study conducted?

We used publicly available TCGA data. This was part of a very large, NIH-funded project where large sequencing centers performed lots of analyses on many different types of tumors, and they made the information publicly available so that researchers could go and mine the data for interesting things that, as individual labs, we would not be able to afford to do—things like whole-exome sequencing, DNA methylation analysis, and they did a gene expression analysis.

We used all that data, and combinatorial analyses, to look at cervical cancers. We had a little bit of a hint that HPV silencing may be going on, because some of our coauthors had discovered in head and neck cancer that this subset exists. So we were looking to see if this was also true in cervical cancer.

And what did your findings show?

We found a subset of cervical tumors that do not express important HPV genes. These are oncogenes E6 and E7, which are the most important oncogenes, and they’re the ones that drive a lot of cervical cancers. We found that tumors that do not express HPV have a different methylation profile and a different mutational profile, and that comes back around full circle to show that these patients could possibly be treated differently.

The tumors that do express HPV show increased expression of the inflammatory response genes compared with the tumors that don’t express HPV. This indicates an ongoing stimulant to recruit the immune response to the HPV-active tumors. The HPV-active tumors also express CTLA-4, PD-L1, and TIGIT. So taken together, we think that immune checkpoint inhibitor therapy would work better on the HPV-active than the HPV-inactive tumors.

Are there trials out there looking at the use of immune checkpoint inhibitor therapy in cervical cancer?

Currently, there are ongoing immune checkpoint inhibitor trials in cervical cancer. There’s some with anti¬–PD-1, anti–PD-L1, and anti–CTLA-4. It would be interesting for these trials to be retrospectively analyzed for the association of response with the expression of the HPV E6 and E7 oncogenes.

One of the cool and very surprising things we found was that about half of the HPV-inactive tumors had mutations in the TP53 gene. Many cervical cancers also demonstrate de novo resistance to cisplatin therapy, and we know that cisplatin kills in a TP53-dependent manner. Therefore, the tumors with the TP53 mutations may be resistant to the DNA-damaging agents, like cisplatin. So it would be important for physicians to test for the TP53 mutation, which would almost exclusively be found in an HPV-inactive tumor, and look for associations with cisplatin resistance. So that is one of the ongoing things that we may be looking into: correlating outcomes with whether or not their tumors are active or inactive.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication